IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-55006-2.html
   My bibliography  Save this article

Development of a RIPK1 degrader to enhance antitumor immunity

Author

Listed:
  • Xin Yu

    (Baylor College of Medicine
    Baylor College of Medicine)

  • Dong Lu

    (Baylor College of Medicine)

  • Xiaoli Qi

    (Baylor College of Medicine
    Baylor College of Medicine)

  • Rishi Ram Paudel

    (Baylor College of Medicine
    Baylor College of Medicine)

  • Hanfeng Lin

    (Baylor College of Medicine
    Baylor College of Medicine)

  • Bryan L. Holloman

    (Baylor College of Medicine
    Baylor College of Medicine)

  • Feng Jin

    (Baylor College of Medicine)

  • Longyong Xu

    (Baylor College of Medicine
    The University of Texas M.D. Anderson Cancer Center)

  • Lang Ding

    (Janelia Research Campus)

  • Weiyi Peng

    (University of Houston)

  • Meng C. Wang

    (Janelia Research Campus)

  • Xi Chen

    (Baylor College of Medicine
    The University of Texas M.D. Anderson Cancer Center
    The University of Texas M.D. Anderson Cancer Center)

  • Jin Wang

    (Baylor College of Medicine
    Baylor College of Medicine
    Baylor College of Medicine)

Abstract

The scaffolding function of receptor interacting protein kinase 1 (RIPK1) confers intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs) and emerges as a promising target for improving cancer immunotherapies. To address the challenge posed by a poorly defined binding pocket within the intermediate domain of RIPK1, here we harness proteolysis targeting chimera (PROTAC) technology to develop a RIPK1 degrader, LD4172. LD4172 exhibits potent and selective RIPK1 degradation both in vitro and in vivo. Degradation of RIPK1 by LD4172 triggers immunogenic cell death, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy in female C57BL/6J mice. This work reports a RIPK1 degrader that serves as a chemical probe for investigating the scaffolding functions of RIPK1 and as a potential therapeutic agent to enhance tumor responses to ICBs therapy.

Suggested Citation

  • Xin Yu & Dong Lu & Xiaoli Qi & Rishi Ram Paudel & Hanfeng Lin & Bryan L. Holloman & Feng Jin & Longyong Xu & Lang Ding & Weiyi Peng & Meng C. Wang & Xi Chen & Jin Wang, 2024. "Development of a RIPK1 degrader to enhance antitumor immunity," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-55006-2
    DOI: 10.1038/s41467-024-55006-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-55006-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-55006-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-55006-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.